Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.07 USD | +2.26% | -5.13% | -22.77% |
03-13 | Craig-Hallum Adjusts Price Target on Bioventus to $9 From $6, Maintains Buy Rating | MT |
03-12 | Transcript : Bioventus Inc., Q4 2023 Earnings Call, Mar 12, 2024 |
Business Summary
Number of employees: 970
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pain Treatments
43.1
%
| 216 | 42.2 % | 221 | 43.1 % | +2.07% |
Surgical Solutions
30.1
%
| 141 | 27.6 % | 154 | 30.1 % | +9.43% |
Restorative Therapies
26.8
%
| 155 | 30.2 % | 137 | 26.8 % | -11.36% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
87.8
%
| 455 | 88.9 % | 450 | 87.8 % | -1.18% |
International
12.2
%
| 57 | 11.1 % | 62 | 12.2 % | +9.88% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Robert Claypoole
CEO | Chief Executive Officer | - | 01-09 |
Mark Singleton
DFI | Director of Finance/CFO | 55 | 22-03-20 |
Katrina Church
CMP | Compliance Officer | 62 | - |
Dave Crawford
IRC | Investor Relations Contact | - | 21-08-22 |
Helen Leupold
HRO | Human Resources Officer | - | 22-05-31 |
Anthony Doyle
PRN | Corporate Officer/Principal | - | 17-03-31 |
Andrew Hosmer
PRN | Corporate Officer/Principal | - | 12-04-30 |
Anthony D'Adamio
LAW | General Counsel | 63 | 17-07-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
William Hawkins
CHM | Chairman | 70 | 16-06-29 |
Guy Nohra
BRD | Director/Board Member | 63 | 19-12-31 |
Martin Sutter
BRD | Director/Board Member | 68 | 16-06-29 |
Susan Stalnecker
BRD | Director/Board Member | 71 | 20-08-31 |
Guido Neels
BRD | Director/Board Member | 75 | 19-12-31 |
Director/Board Member | 53 | 23-01-07 | |
Mary Ladone
BRD | Director/Board Member | 57 | 21-07-14 |
Philip G. Cowdy
BRD | Director/Board Member | 56 | 16-06-29 |
Patrick Beyer
BRD | Director/Board Member | 58 | 21-10-28 |
Director/Board Member | 54 | 21-12-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 15,786,737 | 0 | 0 | 66.64 % |
Stock B | 1 | 63,827,617 | 53,051,569 ( 83.12 %) | 0 |
Company contact information
Sector
Sales per Business
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.77% | 260M | |
+72.92% | 12.36B | |
-19.68% | 7.83B | |
+16.20% | 7.21B | |
+6.78% | 5.97B | |
+7.49% | 5.14B | |
+23.97% | 4.43B | |
-18.91% | 3.9B | |
-41.54% | 2.2B | |
+1.24% | 2.02B |
- Stock Market
- Equities
- BVS Stock
- Company Bioventus Inc.